CASE REPORT


Rosuvastatin was Effective in Acute Heart Failure and Slow Coronary Flow: A Hypothesis-generating Case Report



Alessio Arrivi 1, Gaetano Tanzilli 2, Paolo Emilio Puddu 2 , *, Luca Iannucci 2, Enrico Mangieri 2
1 From the Interventional Cardiology Unit, Santa Maria University Hospital, Terni, Italy
2 From the Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatrical Sciences, Sapienza University of Rome, Italy


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 1527
Abstract HTML Views: 677
PDF Downloads: 428
Total Views/Downloads: 2632
Unique Statistics:

Full-Text HTML Views: 641
Abstract HTML Views: 386
PDF Downloads: 299
Total Views/Downloads: 1326



Creative Commons License
© Arrivi et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Sapienza University of Rome, Department of Cardiovascular, Respiratory, Nephrological, Anesthesio-logical and Geriatrical Sciences, Laboratory of Biotechnologies Applied to Cardiovascular Medicine, Viale del Policlinico, 155, Rome 00161, Italy.; Tel: +39-0649972659; Fax: +39-064453891; E-mail: paoloemilio.puddu@uniroma1.it


Abstract

Slow coronary flow phenomenon (SCFP) is characterized by angiographically normal coronary arteries with delayed run-off of contrast medium across the vasculature. Its etiology and clinical significance are still not completely known; however, acute congestive heart failure (CHF) is rare in this context. A 71 year-old woman with SCFP presented with acute CHF complicated by ventricular tachycardia. Treated with rosuvastatin (20 mg/day for 6 days) and inotropic drug infusion she had a complete recovery of left ventricular function and normalization of serum levels of the high-sensitivity C-reactive protein (hs-CRP), which were increased (3.6 mg/L) during the acute phase. This case illustrates that the anti-inflammatory properties of rosuvastatin may deserve specific clinical tests not only during the chronic phase but also in the acute phase of CHF patients.

Keywords: Rosuvastatin, acute heart failure, slow coronary flow..